Optimism In War On Cancer On The Rise, As Biotech Companies Roll Out More Wins - Financial News Media
CONTINUED... Read this and more news for Oncolytics Biotech at: In other recent industry developments and happenings in the m ...
Oncolytics making progress in 2025 with regulatory, clinical advancements
Biotech continues to make good progress in 2025 with key regulatory and clinical advancements, reinforcing pelareorep’s ...
Oncolytics Biotech® Strengthens Its Pipeline in 2025 with Key Pancreatic and Anal Cancer Advances in Addition to Metastatic Breast Cancer
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for ...
Optimism in War on Cancer on the Rise, as Biotech Companies Roll Out More Wins
Detailed price information for Immunitybio Inc (IBRX-Q) from The Globe and Mail including charting and trades.
Oncolytics Biotech faces Nasdaq delisting over share price
SAN DIEGO and CALGARY, AB - Oncolytics Biotech Inc. (NASDAQ: NASDAQ:ONCY) (TSX: ONC), a biotechnology firm focused on immunotherapy for cancer, has received a notification from the Nasdaq regarding ...
Oncolytics receives noncompliance notification from Nasdaq
Oncolytics (ONCY) announced that it received a delinquency notification letter from Nasdaq indicating that the company is not currently in ...
Oncolytics Biotech® Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for ...
Replimune: A Misunderstood Contender In Oncolytics
Replimune's innovative cancer therapies, strong cash reserves, and FDA support position it to disrupt oncology markets. Click ...
AFP7d
Novotech Releases Comprehensive Report on Oncolytic Virus Therapy
that partners with biotech and small to mid-size pharma companies to accelerate the development of advanced and novel therapeutics, has released its latest report, Oncolytic Virus Therapy ...
HC Wainwright Reaffirms Buy Rating for Oncolytics Biotech (NASDAQ:ONCY)
Oncolytics Biotech (NASDAQ:ONCY – Get Free Report)‘s stock had its “buy” rating reissued by HC Wainwright in a report released on Monday,Benzinga reports. They presently have a $5.00 target price on ...